Chemerin is an adipokine that plays a crucial role in adipocyte differentiation and development, as well as in glucose and lipid metabolism. High levels of asymmetric dimethylarginine (ADMA), a naturally occurring product of metabolism, inhibit nitric oxide (NO) synthesis and are related to endothelial dysfunction. The aim of this study was to investigate the effect of vildagliptin therapy and the combination of pioglitazone and glimepiride on the levels of NO, ADMA, and chemerin in diabetic patients. The study was conducted on 140 subjects, including 40 apparently healthy subjects, and 100 type 2 diabetic obese patients; 50 of them were treated with vildagliptin, and the other 50 patients revived combination of pioglitazone and glimepiride, both groups were treated for 12 months. For all participants, the levels of fasting blood glucose (FBG), fructosamine, HbA1c, lipid profile, ADMA, NO, and chemerin were determined. The levels of those parameters were compared before and after treatment. In both treated groups, levels of FBG, fructosamine, HbA1c, TC, and LDL-C decreased after treatment. Levels of chemerin and ADMA decreased significantly after treatment, whereas the levels of NO increased compared to the baseline values. Additionally, levels of chemerin and ADMA in the group treated with combination of pioglitazone and glimepiride were significantly lower compared to the group treated with vildagliptin. In conclusion, treatment with combination of pioglitazone and glimepiride had a favorable effect on chemerin and ADMA levels in obese type 2 diabetic patients.
Asymmetric dimethylarginine Chemerin Nitric oxide Obesity Type 2 diabetes mellitus
Body mass index
Fasting blood glucose
High-density lipoprotein cholesterol
Low-density lipoprotein cholesterol
Nitric oxide synthase
Proliferator-activated receptor gamma
Type 2 diabetes mellitus
This is a preview of subscription content, log in to check access.
The authors are thankful to the staff members of the outpatients’ clinic of diabetes in Suez Hospitals for their help in collection of samples.
All authors have contributed significantly to the study. Dina M. Abo-Elmatty and Hussein Al-Sawaf designed the study. Ahmed A. Youssef and Omnia I Ezzat were responsible for collection of samples and laboratory work. Eman T. Mehanna was responsible for data analysis. Ahmed A. Youssef and Eman T. Mehanna wrote the manuscript. This work was funded by the authors.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
The present study was conducted according to the principles of the Declaration of Helsinki. The study protocol was approved by the Suez Canal University Research Ethics Committee (code # 201611MH2).
Informed consent was obtained from all individual participants included in the study.
Mahmuda F, Akhter M, Nath RK. Obesity in the pathogenesis of type 2 diabetes. KYAMC J. 2017;4:357–61.CrossRefGoogle Scholar
Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105:141–50.CrossRefPubMedGoogle Scholar
Ballak DB, van Diepen JA, Moschen AR, Jansen HJ, Hijmans A, Groenhof GJ, et al. IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun. 2014;5:4711.CrossRefPubMedGoogle Scholar
Piya MK, McTernan PG, Kumar S. Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin. J Endocrinol. 2013;216:T1–T15.CrossRefPubMedGoogle Scholar
Ekpe EE, Ekpe VE. Chemical pathology of chemerin and its link to obesity and type 2 diabetes mellitus: a review. Biochem Mol Biol. 2017;2:37–9.CrossRefGoogle Scholar
Neuparth MJ, Proença JB, Santos-Silva A, Coimbra S. Adipokines, oxidized low-density lipoprotein, and C-reactive protein levels in lean, overweight, and obese Portuguese patients with type 2 diabetes. ISRN Obes. 2013;2013:142097.PubMedPubMedCentralGoogle Scholar
Flehmig G, Scholz M, Klöting N, Fasshauer M, Tönjes A, Stumvoll M, et al. Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation. PLoS One. 2014;9:e99785.CrossRefPubMedPubMedCentralGoogle Scholar
Brinkmann SJ, Wörner EA, Leeuwen PA. Strict glucose control and artificial regulation of the NO–ADMA–DDAH system in order to prevent endothelial dysfunction. J Physiol. 2016;594:2775–6.CrossRefPubMedPubMedCentralGoogle Scholar
Brinkmann SJ, de Boer MC, Buijs N, van Leeuwen PA. Asymmetric dimethylarginine and critical illness. Curr Opin Clin Nutr Metab Care. 2014;17:90–7.PubMedGoogle Scholar
Lukashevich V, Del Prato S, Araga M, Kothny W. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab. 2014;16:403–9.CrossRefPubMedGoogle Scholar
Derosa G, Ragonesi PD, Carbone A, Fogari E, D’Angelo A, Cicero AF, et al. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin Pharmacother. 2012;13:2581–91.CrossRefPubMedGoogle Scholar
Hu W, Yu Q, Zhang J, Liu D. Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats. Inflammation. 2012;35:1287–93.CrossRefPubMedGoogle Scholar
Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38:355–64.CrossRefPubMedGoogle Scholar
Chaea SY, Lee M, Kim SW, Bae YH. Protection of insulin secreting cells from nitric oxide induced cellular damage by cross linked hemoglobin. Biomaterials. 2004;25:843–50.CrossRefGoogle Scholar
Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Invest. 2015;21:57–74.Google Scholar
Cheon DY, Kang JG, Lee SJ, Ihm SH, Lee EJ, Choi MG, et al. Serum chemerin levels are associated with visceral adiposity, independent of waist circumference, in newly diagnosed type 2 diabetic subjects. Yonsei Med J. 2017;58:319–25.CrossRefPubMedPubMedCentralGoogle Scholar
Fülöp P, Seres I, Lőrincz H, Harangi M, Somodi S, Paragh G. Association of chemerin with oxidative stress, inflammation and classical adipokines in non-diabetic obese patients. J Cell Mol Med. 2014;18:1313–20.CrossRefPubMedPubMedCentralGoogle Scholar
Esteghamati A, Ghasemiesfe M, Mousavizadeh M, Noshad S, Nakhjavani M. Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes. J Diabetes Investig. 2014;5:327–32.CrossRefPubMedGoogle Scholar
Yu S, Zhang Y, Li MZ, Xu H, Wang Q, Song J, et al. Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients. Chin Med J. 2012;125:3440–4.PubMedGoogle Scholar
Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr Pharm Des. 2008;14:2613–8.CrossRefPubMedGoogle Scholar
Pereira EC, Ferderbar S, Bertolami MC, Faludi AA, Monte O, Xavier HT, et al. Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus. Clin Biochem. 2008;41:1454–60.CrossRefPubMedGoogle Scholar
Sarwar N, Aspelund T, Eiriksdottir G, Gobin R, Seshasai SR, Forouhi NG, et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med. 2010;7:e1000278.CrossRefPubMedPubMedCentralGoogle Scholar
Ali OA, Chapman M, Nguyen TH, Chirkov YY, Heresztyn T, Mundisugih J, et al. Interactions between inflammatory activation and endothelial dysfunction selectively modulate valve disease progression in patients with bicuspid aortic valve. Heart. 2014;100:800–5.CrossRefPubMedGoogle Scholar
de Giorgis T, Marcovecchio ML, Giannini C, Chiavaroli V, Chiarelli F, Mohn A. Blood pressure from childhood to adolescence in obese youths in relation to insulin resistance and asymmetric dimethylarginine. J Endocrinol Investig. 2016;39:169–76.CrossRefGoogle Scholar
Baum C, Johannsen SS, Zeller T, Atzler D, Ojeda FM, Wild PS, et al. ADMA and arginine derivatives in relation to non-invasive vascular function in the general population. Atherosclerosis. 2016;244:149–56.CrossRefPubMedGoogle Scholar
Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev. 2010;6:82–90.CrossRefPubMedPubMedCentralGoogle Scholar
Duvnjak L, Blaslov K. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2016;8:26.CrossRefPubMedPubMedCentralGoogle Scholar
Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes. 2007;56:3006–13.CrossRefPubMedGoogle Scholar
Cakirca M, Karatoprak C, Zorlu M, Kiskac M, Kanat M, Cikrikcioglu MA, et al. Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients. Drug Des Devel Ther. 2014;8:239–43.PubMedPubMedCentralGoogle Scholar
Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547–54.CrossRefPubMedGoogle Scholar
Kulkarni KB, Gade PR, Muglikar AG, Bhavthankar SS. A study of glimepiride versus metformin plus glimepiride with respect to glycemic control and lipid profile in type II diabetes mellitus patients. MedPulse – Int Med J. 2016;3:88–91.Google Scholar
Wakino S, Hayashi K, Tatematsu S, Hasegawa K, Takamatsu I, Kanda T, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res. 2005;28:255–62.CrossRefPubMedGoogle Scholar
Tahara N, Yamagishi SI, Mizoguchi M, Tahara A, Imaizumi T. Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. Rejuvenation Res. 2013;16:344–51.CrossRefPubMedGoogle Scholar
Vernochet C, Peres SB, Davis KE, McDonald ME, Qiang L, Wang H, et al. C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists. Mol Cell Biol. 2009;29:4714–28.CrossRefPubMedPubMedCentralGoogle Scholar